BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 15713485)

  • 1. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
    Shia S; Stamos J; Kirchhofer D; Fan B; Wu J; Corpuz RT; Santell L; Lazarus RA; Eigenbrot C
    J Mol Biol; 2005 Mar; 346(5):1335-49. PubMed ID: 15713485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocyte growth factor activator (HGFA): molecular structure and interactions with HGFA inhibitor-1 (HAI-1).
    Eigenbrot C; Ganesan R; Kirchhofer D
    FEBS J; 2010 May; 277(10):2215-22. PubMed ID: 20402765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1.
    Kirchhofer D; Peek M; Li W; Stamos J; Eigenbrot C; Kadkhodayan S; Elliott JM; Corpuz RT; Lazarus RA; Moran P
    J Biol Chem; 2003 Sep; 278(38):36341-9. PubMed ID: 12815039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mouse hepatocyte growth factor (HGF) activator inhibitor type 2 lacking the first Kunitz domain potently inhibits the HGF activator.
    Kataoka H; Itoh H; Nuki Y; Hamasuna R; Naganuma S; Kitamura N; Shimomura T
    Biochem Biophys Res Commun; 2002 Jan; 290(3):1096-100. PubMed ID: 11798188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
    Kirchhofer D; Peek M; Lipari MT; Billeci K; Fan B; Moran P
    FEBS Lett; 2005 Mar; 579(9):1945-50. PubMed ID: 15792801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor.
    Hashimoto T; Kato M; Shimomura T; Kitamura N
    FEBS J; 2010 Dec; 277(23):4888-900. PubMed ID: 20977675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.
    Kataoka H; Hamasuna R; Itoh H; Kitamura N; Koono M
    Cancer Res; 2000 Nov; 60(21):6148-59. PubMed ID: 11085539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases.
    Mukai S; Fukushima T; Naka D; Tanaka H; Osada Y; Kataoka H
    FEBS J; 2008 Mar; 275(5):1003-17. PubMed ID: 18221492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocyte growth factor activator inhibitor type 1 inhibits protease activity and proteolytic activation of human airway trypsin-like protease.
    Kato M; Hashimoto T; Shimomura T; Kataoka H; Ohi H; Kitamura N
    J Biochem; 2012 Feb; 151(2):179-87. PubMed ID: 22023801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pericellular activation of hepatocyte growth factor/scatter factor (HGF/SF) in colorectal carcinomas: roles of HGF activator (HGFA) and HGFA inhibitor type 1 (HAI-1).
    Kataoka H; Itoh H; Hamasuna R; Meng JY; Koono M
    Hum Cell; 2001 Mar; 14(1):83-93. PubMed ID: 11436357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
    Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
    J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defect of pro-hepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis.
    Marchand-Adam S; Fabre A; Mailleux AA; Marchal J; Quesnel C; Kataoka H; Aubier M; Dehoux M; Soler P; Crestani B
    Am J Respir Crit Care Med; 2006 Jul; 174(1):58-66. PubMed ID: 16574935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in plasma levels of hepatocyte growth factor and its associated factors during pregnancy.
    Watanabe T; Sakata Y; Matsubara S; Yamagishi T; Nagaike K; Kuwata T; Suzuki M
    J Obstet Gynaecol Res; 2006 Feb; 32(1):10-4. PubMed ID: 16445520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
    Parr C; Jiang WG
    Int J Cancer; 2006 Sep; 119(5):1176-83. PubMed ID: 16557597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte growth factor activator (HGFA): a serine protease that links tissue injury to activation of hepatocyte growth factor.
    Miyazawa K
    FEBS J; 2010 May; 277(10):2208-14. PubMed ID: 20402766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The hepatocyte growth factor regulatory factors in human breast cancer.
    Parr C; Watkins G; Mansel RE; Jiang WG
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):202-11. PubMed ID: 14734471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocyte growth factor activator inhibitor type 2 lacking the first Kunitz-type serine proteinase inhibitor domain is a predominant product in mouse but not in human.
    Itoh H; Kataoka H; Hamasuna R; Kitamura N; Koono M
    Biochem Biophys Res Commun; 1999 Feb; 255(3):740-8. PubMed ID: 10049781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expressions of molecules associated with hepatocyte growth factor activation after hepatectomy in liver cirrhosis.
    Kaido T; Oe H; Yoshikawa A; Okajima A; Imamura M
    Hepatogastroenterology; 2004; 51(56):547-51. PubMed ID: 15086199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
    Franco FM; Jones DE; Harris PK; Han Z; Wildman SA; Jarvis CM; Janetka JW
    Bioorg Med Chem; 2015 May; 23(10):2328-43. PubMed ID: 25882520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist.
    Kirchhofer D; Lipari MT; Santell L; Billeci KL; Maun HR; Sandoval WN; Moran P; Ridgway J; Eigenbrot C; Lazarus RA
    Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5306-11. PubMed ID: 17372204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.